Latham & Watkins Advises the Underwriters in Castle Bioscience’s Public Offering

Castle Biosciences, Inc., has announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a public offering price of US$58.00 per share. The gross proceeds to Castle from the offering, including the shares sold pursuant to the underwriters’ option, before deducting the underwriting discounts and commissions and other offering expenses payable by Castle, were US$266.8 million. 

Latham & Watkins LLP represents the underwriters in the transaction with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Anthony Gostanian and Emily Henderson.